Medicare

New & Noteworthy

What to Know About Pharmacy Benefit Managers and Federal Efforts at Regulation

The top three pharmacy benefit managers (PBMs) manage 79% of prescription drug claims on behalf of 270 million people. We look at the role PBMs play in influencing drug costs and access to medicines, as well as efforts to regulate them.

State Profiles for Dual-Eligible Individuals

This data collection draws on Medicare and Medicaid administrative data to present national and state-level information on people who are covered by both Medicare and Medicaid, referred to as dual-eligible individuals (also known as dually-enrolled beneficiaries).

Data Visualization

The Facts About Medicare Spending

This interactive provides the facts on Medicare spending. Medicare, which serves 67 million people and accounts for 12 percent of the federal budget and 21 percent of national health spending, is often the focus of discussions about health expenditures, health care affordability and the sustainability of federal health programs.

Explore data on enrollment growth, Medicare spending trends overall and per person, growth in Medicare spending relative to private insurance, spending on benefits and Medicare Advantage, Part A trust fund solvency challenges, and growth in out-of-pocket spending by beneficiaries.

Related: FAQs on Medicare Financing and Trust Fund Solvency

Read More

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here

Filter

1,461 - 1,470 of 1,587 Results

  • Analysis of Benefits Offered By Medicare HMOs, 1999: Complexities and Implications

    Report

    This report analyzes supplemental benefits offered and premiums charged by Medicare HMOs nationwide in 1999, assessing the generosity of selected benefits, including prescription drugs. The study finds that the level of monthly premiums charged by Medicare HMOs, and the generosity of many supplemental benefits, especially prescription drugs, vary widely within and across markets.

  • Medicare Advantage 2012 Data Spotlight: Enrollment Market Update

    Report

    This data spotlight examines the growth in private Medicare Advantage plan enrollment in 2012, with a record 13 million Medicare beneficiaries enrolled as of March, representing 27 percent of all Medicare beneficiaries. Enrollment jumped by more than 1 million enrollees from the previous year and increased in every state except Alaska and New Hampshire.

  • Toplines: July/August 2005 Health Poll Report Survey

    Poll Finding

    Health News Index July/August, 2005 These toplines provide the complete survey questions and responses to the July/August 2005 Kaiser Health Poll Report, a bimonthly report designed to provide key tracking information on public opinion about health care topics to journalists, policymakers and the general public.

  • Tracking Poll Finds Seniors Split on Medicare Drug Benefit

    Poll Finding

    Tracking Poll Finds Seniors Now Split on Medicare Drug Benefit This August tracking survey shows modest progress in seniors' knowledge about the Medicare drug benefit. Also, for the first time, the tracking poll shows seniors are as likely to say that they have a favorable impression of the drug benefit as an unfavorable one.

  • Medicare Prescription Drug Improvement and Modernization Act Implementation Timeline: June 2004 – December 2006 Key Dates

    Report

    Key Implementation Dates for the Medicare Prescription Drug Benefit This timeline presents important dates and deadlines of key implementation activities related to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). It runs from the beginning of 2005 through the end of 2006, the first year of the new Medicare drug benefit.

  • Medicare Part D 2009 Data Spotlight: The Coverage Gap

    Report

    This Medicare Part D data spotlight examines the coverage gap, or "doughnut hole," in Medicare drug plans available in 2009. While in the gap in coverage, Part D enrollees (other than those receiving low-income subsidies) are required to pay 100 percent of total drug costs until they reach the catastrophic coverage level.